Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 4/20 | 0.37 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14592069 | 0.73 | SLC6A2 (0.47) | CHRM2CHRM3HRH3SLC6A2SLC6A3 | |
| SCHEMBL192536 | 0.71 | MCL1 (0.51) | USP30 | |
| SCHEMBL29015574 | 0.71 | MCL1 (0.51) | USP30 | |
| SCHEMBL192535 | 0.71 | MCL1 (0.51) | USP30 | |
| SCHEMBL6842708 | 0.71 | MCL1 (0.51) | USP30 | |
| SCHEMBL23452261 | 0.71 | MCL1 (0.51) | USP30 | |
| SCHEMBL9544995 | 0.71 | MCL1 (0.51) | USP30 | |
| SCHEMBL252870 | 0.71 | MCL1 (0.51) | USP30 | |
| SCHEMBL949539 | 0.71 | ATM (0.49) | HRH3SLC6A2SLC6A3KCNH2 | |
| SCHEMBL949541 | 0.71 | ATM (0.49) | HRH3SLC6A2SLC6A3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050027007-A1 | Allylamides useful in the treatment of alzheimer's disease | ELAN PHARMACEUTICALS, INC. | 2005-02-03 | — | — | US | disclosed |
| EP-0617968-B1 | HIV protease inhibitors in pharmaceutical combinations for the treatment of AIDS | MERCK & CO INC (US) | 2003-01-08 | — | — | EP | disclosed |
| EP-0541168-B1 | HIV protease inhibitors useful for the treatment of aids | MERCK & CO INC (US) | 1998-03-11 | — | — | EP | disclosed |
| US-5717097-A | N-(2(R)-HYDROXY-1(S)-INDANYL)-2(R)-PHENYLMETHYL-4(S)-(HYDROXY) -5-SUBSTITUTED-N'-(T-BUTYLCARBAMOYL)PIPERAZINYL))PENTANEAMIDE COMPOUNDS | MERCK & CO., INC. (US) | 1998-02-10 | — | — | US | disclosed |
| US-5668132-A | HIV Protease inhibitors useful for the treatment of AIDS | MERCK & CO., INC. (US) | 1997-09-16 | — | — | US | disclosed |
| US-5527799-A | ADMINISTERING MIXTURE OF TWO COMPOUNDS AND OPTIONAL AZT | MERCK & CO., INC. (US) | 1996-06-18 | — | — | US | disclosed |
| EP-0696277-A1 | HIV PROTEASE INHIBITORS USEFUL FOR THE TREATMENT OF AIDS | MERCK & CO. INC. (US) | 1996-02-14 | — | — | EP | disclosed |
| US-5413999-A | structure is piperazine containing amides | MERCK & CO., INC. (US) | 1995-05-09 | — | — | US | disclosed |
| WO-1994026717-A1 | HIV PROTEASE INHIBITORS USEFUL FOR THE TREATMENT OF AIDS | MERCK & CO., INC. (US) | 1994-11-24 | — | — | WO | disclosed |
| WO-1994022480-A1 | HIV PROTEASE INHIBITORS IN PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF AIDS | MERCK & CO., INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| EP-0617968-A1 | HIV protease inhibitors in pharmaceutical combinant for the treatment of AIDS | MERCK & CO. INC. (US) | 1994-10-05 | — | — | EP | disclosed |
| WO-1993009096-A1 | HIV PROTEASE INHIBITORS USEFUL FOR THE TREATMENT OF AIDS | MERCK & CO., INC. (US) | 1993-05-13 | — | — | WO | disclosed |
| EP-0541168-A1 | HIV protease inhibitors useful for the treatment of aids | MERCK & CO. INC. (US) | 1993-05-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050027007-A1 | Allylamides useful in the treatment of alzheimer's disease | BACE1, BACE2, APBA1 | CHRM2 1425/4885CHRM3 2735/4885USP30 2983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.